Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin vs Acarbose in Type 2 Diabetes
NCT05035849Completed
- Sponsor
- Nanjing First Hospital
- Start
- Jan 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sitagliptin and acarbose in type 2 diabetes mellitus (T2DM), sponsored by Nanjing First Hospital. Primary endpoint: Glycemic variations at 3 months. Started Jan 2020; status: completed.
02
Drugs
sitagliptinacarbose
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05035849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05035849.